Organon & Co. CEO Kevin Ali is the first to admit that the company faced a lot of skepticism when it spun out of Merck & Co., Inc. with three seemingly disparate sets of assets – established products, biosimilars and women’s health – with plans to most aggressively invest in women’s health for growth. Ali is also the first to note that the company has delivered on its promises across all three areas during its first year.
“Investors and analysts at the very beginning when we first spun out were wondering how these three pieces of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?